Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion
Aparna R. Parikh, MD
Innovations in Oncology Learning Center From Guidelines to Practice: Gastrointestinal Cancers
Sara Lonardi, MD
Alan Venook, MD
Expert Viewpoint: Optimizing Breast Cancer Treatment
William J. Gradishar, MD
Erica L. Mayer, MD, MPH
Peter Schmid, FRCP, MD, PhD
Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC
Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence
Management of HER2-Low MBC Following First-Line Disease Progression
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
The Evolving Treatment Landscape for MBC: Emerging Therapies
First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study
Emerging Treatment Approaches for EBC
First-line Treatment of MSI-H/dMMR mCRC: The Role of Immunotherapy
The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer
Expert Opinion: Key Insights on GI Malignancies—Integrating NCCN Clinical Practice Guidelines Into Practice
Innovations in Oncology Learning Center: From Guidelines to Practice—Breast Cancer
Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances
Nicoletta Colombo, MD
Innovations in Oncology Learning Center From Guidelines to Practice: Genitourinary Cancers
Ignacio Duran, MD
Wenxin Xu, MD
Sandy Srinivas, MD
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.